Critical Analysis: Global Partner Acquisition Corp II (NASDAQ:GPAC) and Koninklijke DSM (OTCMKTS:RDSMY)

Global Partner Acquisition Corp II (NASDAQ:GPAC) and Koninklijke DSM (OTCMKTS:RDSMY) are both computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Profitability

This table compares Global Partner Acquisition Corp II and Koninklijke DSM’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Global Partner Acquisition Corp II	N/A	-0.90%	-8.69%
Koninklijke DSM	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Global Partner Acquisition Corp II and Koninklijke DSM, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Global Partner Acquisition Corp II	1	0	0	0	1.00
Koninklijke DSM	0	0	0	0	0.00

Volatility & Risk

Global Partner Acquisition Corp II has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500. Comparatively, Koninklijke DSM has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.

Institutional and Insider Ownership

32.8% of Global Partner Acquisition Corp II shares are owned by institutional investors. Comparatively, 0.2% of Koninklijke DSM shares are owned by institutional investors. 65.6% of Global Partner Acquisition Corp II shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Global Partner Acquisition Corp II and Koninklijke DSM”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Partner Acquisition Corp II	N/A	N/A	$140,000.00	N/A	N/A
Koninklijke DSM	$10.89 billion	2.17	$1.98 billion	N/A	N/A

Koninklijke DSM has higher revenue and earnings than Global Partner Acquisition Corp II.

Summary

Koninklijke DSM beats Global Partner Acquisition Corp II on 5 of the 8 factors compared between the two stocks.

About Global Partner Acquisition Corp II

Global Partner Acquisition Corp II does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in Rye Brook, New York.

About Koninklijke DSM

Koninklijke DSM N.V., a science-based company, engages in nutrition, health, and sustainable living businesses in the Netherlands, Switzerland, rest of Europe, North America, Latin America, China, rest of Asia, and internationally. It operates through Nutrition, Materials, and Innovation Center segments. The Nutrition segment offers animal nutrition and health products, including vitamins, premixes, carotenoids, enzymes, microbes, and eubiotics; human nutrition and health products comprising vitamins, nutritional lipids, minerals, carotenoids, nutraceuticals, digestive enzymes, probiotics, and prebiotics, as well as active pharmaceutical ingredients; premix, market-ready solutions, and personalized nutrition; human milk oligosaccharides; and skin and sun care, hair care, and aroma ingredients; omega-3 fatty acids; and specialty food enzymes, cultures, bio-preservation, texturizing hydrocolloids, sugar reduction, and savory taste solutions. The Materials segment provides specialty plastics used in components for the electrical and electronics, automotive, flexible food-packaging, and consumer goods industries; and Dyneema, a fiber solution for use in personal protection, workwear, sports apparel, outdoor equipment, ropes and slings, synthetic chains, and nets for the aquaculture, and renewable energy sectors. The Innovation Center segment offers biomedical materials, and medical device and material manufacturing technologies in the areas of cardiovascular, continence care, dental, diabetes management, gynecology, neurology, ophthalmology, orthopedic, peripheral vascular, plastic and reconstructive surgery, and wound management. It also commercializes yeast technology yeast for ethanol production. The company was founded in 1902 and is headquartered in Heerlen, the Netherlands.